Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
What does it do?
Incyte is a drug company that focuses on serious diseases like blood cancers and immune system disorders. Their biggest product, Jakafi, helps patients whose bone marrow stops working properly — a rare but life-threatening condition called myelofibrosis. Think of them as a specialist clinic that found a drug most other companies weren't focused on, then built a whole business around it. They also sell other drugs in Europe and are constantly working on new treatments in the lab.
Incyte matters right now because it's one of the few mid-sized biotech companies that is actually profitable — most drug companies at this stage are burning cash. Revenue jumped from $4.2B to $5.1B in a single year, which shows their drugs are still growing in the real world. Investors are also watching closely because Jakafi, their cash cow, will eventually face generic competition, so the race to find the next big drug is on.
How does it make money?
Incyte makes most of its money from selling Jakafi in the US, where it has no generic competition yet — this drug alone drives the majority of their $5.1B in revenue. They also earn royalty payments from Novartis, which sells a version of the same drug outside the US under a different name. On top of that, they sell Iclusig for a type of leukemia and Monjuvi for aggressive blood cancer, adding smaller but growing revenue streams. Net income of $1.3B on $5.1B of revenue means they're keeping about 25 cents of profit for every dollar they bring in, which is solid for a biotech.
Why do investors care?
The growth story is about what comes after Jakafi. Incyte has a pipeline — meaning a list of experimental drugs in testing — that includes treatments for conditions like eczema, lupus, and other cancers. If even one of those becomes a big seller, it could replace or add to the revenue Jakafi generates today. Investors also like that Incyte is already profitable, which means it doesn't need to keep raising money or taking on debt to fund its research. What has to go right: at least one pipeline drug needs to succeed in clinical trials and get approved before Jakafi's patent protection weakens.
Deep Dive
MemberA full investor briefing on Incyte Corporation — history, leadership, risks, and outlook.